exemestane pfizer 25 milligram coated tablets
pfizer healthcare ireland - exemestane - coated tablets - 25 milligram
exemestane 25mg film-coated tablets tablets film-coated
accord healthcare limited - exemestane - tablets film-coated - 25mg
apotex-exemestane
arrotex pharmaceuticals pty ltd - exemestane, quantity: 25 mg - tablet, sugar coated - excipient ingredients: purified talc; sucrose; titanium dioxide; magnesium stearate; colloidal anhydrous silica; acacia; crospovidone; microcrystalline cellulose; mannitol; polysorbate 80; ethanol; shellac; white beeswax; carnauba wax - exemestane is indicated for:,? sequential adjuvant treatment of estrogen receptor positive early breast cancer in postmenopausal women who have received prior adjuvant tamoxifen therapy.,? treatment of estrogen receptor positive advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following antiestrogen therapy.
exemestano accord 25 mg comprimidos recubiertos con pelicula efg
accord healthcare, s.l.u. - exemestano - exemestano....25.00 mg.
exemestano normon 25 mg comprimidos recubiertos con pelicula efg
laboratorios normon, s.a. - exemestano - exemestano....25,00 mg
exemestane-trima
trima trading (1961), israel - exemestane - film coated tablets - exemestane 25 mg - exemestane - - adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer, following 2-3 years of initial adjuvant tamoxifen therapy. - treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone.- treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies.efficacy has not been demonstrated in patients with oestrogen receptor negative status.
exemestan actavis 25 mg
devries & co. ltd - exemestane - film coated tablets - exemestane 25 mg - exemestane - treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer following 2-3 years of initial adjuvant tamoxifen therapy.
exemestane inovamed
inovamed ltd - exemestane 25 mg - film coated tablets - exemestane - exemestane inovamed is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. exemestane inovamed is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. exemestane inovamed is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.
exemestane 25mg film-coated tablets
accord healthcare limited - exemestane - film-coated tablet - exemestane 25 mg - endocrine therapy
exemestane 25mg film-coated tablets
central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - exemestane - film-coated tablet - exemestane 25 mg - endocrine therapy